期刊
CHEMBIOCHEM
卷 17, 期 2, 页码 155-158出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/cbic.201500591
关键词
activation immunotherapeutic; breast cancer; HER2; immunotherapy; nanobody
资金
- Colorado Center for Drug Discovery
- National Institutes of Health [GM100283-01]
We report a rationally designed nanobody activation immunotherapeutic that selectively redirects anti-dinitrophenyl (anti-DNP) antibodies to the surface of HER2-positive breast cancer cells, resulting in their targeted destruction by antibody-dependent cellular cytotoxicity. As nanobodies are relatively easy to express, stable, can be humanized, and can be evolved to potently and selectively bind virtually any disease-relevant cell surface receptor, we anticipate broad utility of this therapeutic strategy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据